RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$57.17
-1.26 (-2.16%)
▼
5d:
-2.66%
30d:
-1.04%
90d:
+15.56%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 4.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 4.8% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$65.03
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$40.38
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $57.17, which is considered fair relative to its 30-day fair value range of $56.32 to $58.88. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.2) compared to its historical average (8.9). At these levels, the market is pricing in 4.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is currently testing key support at $56.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is currently testing key support at $56.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$56.32 -
$58.88
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($59.89)
- NEUTRAL: Market pricing in 4.8% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$56.32 -
$58.88
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$56.90
Resistance Level
$60.44
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.22
Wall Street Target
$59.89
(+4.8%)
Revenue Growth (YoY)
11.0%
Earnings Growth (YoY)
23.2%
Profit Margin
33.9%
Valuation Premium vs History
+4.8% premium
PE vs Historical
10.2 vs 8.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.8%
(market-implied from PE analysis)
1-Year Target
$59.91
(+5%)
2-Year Target
$62.79
(+10%)
3-Year Target
$65.80
(+15%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$57.29
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 7.0%)
$141.89
(+148%)
Base:
(SPY PE: 10.2, Growth: 7.0%)
$69.98
(+22%)
Bear:
(PE: 8.7, Growth: 7.0%)
$59.48
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 31.23 | Current EPS (TTM): $1.89
Bull Case
$129.84
(+122%)
Analyst growth 100.0%, PE expands to 34.4
Base Case
$118.04
(+102%)
Market implied 100.0%, PE stable at 31.2
Bear Case
$40.13
(-31%)
Severe decline -20.0%, PE contracts to 26.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 03, 2026 5:18 PM ET
Data refreshes hourly during market hours. Next update: 6:18 PM
Data refreshes hourly during market hours. Next update: 6:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Terrance P Coyne
SELL
34791 shares
2026-04-01
Terrance P Coyne
SELL
34791 shares
2026-03-23
Terrance P Coyne
SELL
34791 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
